statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kindler is currently the CEO of Centrexion Therapeutics, a privately-held biotechnology company, Senior Advisor to Blackstone, Operating Partner at ARTIS Ventures and Global Chair of GLG Institute, Lupin said in a regulatory filing.

Lupin appoints Jeffrey Kindler, Alfonso 'Chito' Zulueta as Independent directors

Motilal Oswal recommended accumulate rating on Lupin with a target price of Rs 1,550 in its research report dated May 08, 2024.

Neutral Lupin; target of Rs 1,550: Motilal Oswal

Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1868 in its research report dated May 07, 2024.

Buy Lupin; target of Rs 1868: Sharekhan

Prabhudas Lilladher recommended hold rating on Lupin with a target price of Rs 1675 in its research report dated May 07, 2024.

Hold Lupin; target of Rs 1675: Prabhudas Lilladher

High raw material costs dragged Lupin's Q4 net profit to below the Street's estimate, however, the sharp margin improvement provided much cushion to investor sentiment.

Lupin shares slump 5% as Q4 net profit lags Street expectations

Lupin Q4: Revenue came in at Rs 4895.11 crore, up 13 percent from the year-ago quarter of Rs 4,330.3 crore.

Lupin Q4 results: Net profit jumps 52% to Rs 359 crore, revenue up 13%

Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period

Zydus Life gains over 3% on launch of bladder control drug

Mirabegron Extended-Release tablets had estimated annual sales of $1,019 million in the US

Lupin stock climbs nearly 4% on launch of Mirabegron Extended-Release tablets in US

Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1868 in its research report dated April 15, 2024.

As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Lupin is recalling 26,352 bottles of Rifampin Capsules (300 mg), an antibiotic medication in the US market.

Lupin, Glenmark recall drugs in US market: USFDA

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the business of producing, developing, and marketing a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. It operates through the following geographical segments: India, the United States of America, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Watchers	271
52-Wk Low	757.05
52-Wk High	1,704.25

Volume	482,382.00
52-Wk High	1,704.25
52-Wk Low	757.05

Current Price	1,593.40
Prev Close	1,584.70
Open	1,583.95
Dividend Yield	0.62%
50-Day Moving Average	1,621.71
Beta	-0.05
Avg. Volume	1.04M
PE Ratio	37.66

52-Week High	1,704.25
52-Week Low	757.05
Market Capitalization	721.89B
EPS	42.06
Price to Book	5.45
Revenue Per Employee	10.68M
Enterprise Value/EBITDA	14.65

LUPIN.NSE Lupin Ltd

About

Feed

News

Sentiment

Fundamentals